Open AccessLive-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children
Author(s) -
Elizabeth J. McFarland,
Ruth A. Karron,
Petronella Muresan,
Coleen K. Cunningham,
Charlotte Perlowski,
Jennifer Libous,
Jennifer Oliva,
Patrick JeanPhilippe,
Jack Moye,
Elizabeth Schappell,
Emily Barr,
Vivian Rexroad,
Laura Fearn,
Mikhaela Cielo,
Andrew Wiznia,
Jaime G. Deville,
Lijuan Yang,
Cindy Luongo,
Peter L. Collins,
Ursula J. Buchholz
Publication year - 2020
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa049
Subject(s) - virology , immunogenicity , reactogenicity , pneumovirinae , neutralizing antibody , medicine , antibody , titer , virus , immunology , biology , paramyxoviridae , viral disease
Respiratory syncytial virus (RSV) is the leading viral cause of severe pediatric respiratory illness, and vaccines are needed. Live RSV vaccine D46/NS2/N/ΔM2-2-HindIII, attenuated by deletion of the RSV RNA regulatory protein M2-2, is based on previous candidate LID/ΔM2-2 but incorporates prominent differences from MEDI/ΔM2-2, which was more restricted in replication in phase 1.